After-Hours Stock Movers:
Imara Inc. (Nasdaq: IMRA) 22.5% HIGHER; Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
Eargo, Inc. (NASDAQ: EAR) 8.4% LOWER; announced that the record date for its proposed rights offering is October 24, 2022 at 5:00 p.m. Eastern Time (the Record Date).
Travere Therapeutics, Inc. (NASDAQ: TVTX) 5.1% LOWER; announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022 for its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy to be extended by three months.
Amprius Technologies (NYSE: AMPX) 1.6% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $14.00.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。